GENFIT |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.535 EUR | -2.68% |
|
-5.52% | +28.11% |
| Sales 2024 * | 8.24Cr 8.91Cr 744.8Cr | Sales 2025 * | 4.86Cr 5.26Cr 439.13Cr | Capitalization | 23Cr 25Cr 2.09TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9Cr 2.05Cr 171.64Cr | Net income 2025 * | -2.1Cr -2.27Cr -189.71Cr | EV / Sales 2024 * | 2.7 x |
| Net cash position 2024 * | 87.09L 94.15L 79Cr | Net cash position 2025 * | 4.49Cr 4.85Cr 405.61Cr | EV / Sales 2025 * | 3.84 x |
| P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
-49.1
x | Employees | 159 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on GENFIT
More recommendations
More press releases
More news
| 1 day | -2.68% | ||
| 1 week | -5.52% | ||
| Current month | -3.92% | ||
| 1 month | +33.97% | ||
| 3 months | +39.11% | ||
| 6 months | +28.29% | ||
| Current year | +28.11% |
1 week
4.35
5.49
1 month
3.335.79
Current year
3.035.79
1 year
2.845.79
3 years
2.755.79
5 years
2.7520.96
10 years
2.7570.64
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 01/18/01 |
| Founder | 68 | 01/99/01 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 22/21/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 04/21/04 | |
| Founder | 68 | 01/99/01 | |
| Founder | 52 | 15/99/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 4.535 | -2.68% | 68 220 |
| 12/24/12 | 4.66 | -5.19% | 843,182 |
| 11/24/11 | 4.915 | +0.31% | 1,488,378 |
| 10/24/10 | 4.9 | +1.03% | 641,199 |
| 07/24/07 | 4.85 | +1.04% | 930,391 |
Real-time Euronext Paris, June 13, 2024 at 01:55 pm IST
More quotes
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.
The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Calendar
19/09/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.66
EUR
Average target price
9.475
EUR
Spread / Average Target
+103.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.11% | 25Cr | |
| +48.54% | 5.66TCr | |
| +37.49% | 3.93TCr | |
| -6.02% | 3.96TCr | |
| -6.90% | 2.83TCr | |
| +12.97% | 2.64TCr | |
| -16.91% | 2.01TCr | |
| +31.71% | 1.25TCr | |
| +28.18% | 1.25TCr | |
| +0.38% | 1.22TCr |
- Stock Market
- Equities
- GNFT Stock
